RETA Reata Pharmaceuticals Inc.

75.74
+2.75  (+4%)
Previous Close 72.99
Open 74.27
Price To Book -68.23
Market Cap 2,280,254,495
Shares 30,106,344
Volume 225,792
Short Ratio
Av. Daily Volume 232,402

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2019.
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
Phase 3 data due 1H 2020.
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 2 data due 2H 2019.
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2 initial data released March 1, 2018 - endpoints not met.
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 1b interim data released December 11, 2017 - 27% ORR.
Omaveloxolone - REVEAL
Metastatic melanoma
Phase 2 primary endpoint met - noted March 22, 2018.
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 3 enrolment has commenced - May 30, 2019.
Bardoxolone - FALCON
Chronic Kidney Disease
Phase 1 initiation announced June 20, 2018. Initial data due 2Q 2019. Timeline missed. Estimate 3Q.
RTA 1701
Healthy Volunteers

Latest News

  1. Reata Pharmaceuticals, Inc. (RETA) Q2 2019 Earnings Call Transcript
  2. Edited Transcript of RETA earnings conference call or presentation 8-Aug-19 12:00pm GMT
  3. Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates
  4. Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs
  5. Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Paid At A Competitive Rate?
  6. Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Programs on August 8, 2019
  7. The Reata Pharmaceuticals (NASDAQ:RETA) Share Price Has Soared 359%, Delighting Many Shareholders
  8. Hedge Funds Have Never Been This Bullish On Reata Pharmaceuticals, Inc. (RETA)
  9. Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
  10. The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
  11. Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease
  12. Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)
  13. Reata Announces First Patient Enrolled in Phase 3 FALCON Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease
  14. Edited Transcript of RETA earnings conference call or presentation 9-May-19 12:00pm GMT
  15. Reata's drug, Bardoxolone, shows promising results for chronic kidney disease
  16. Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates
  17. Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs
  18. Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference
  19. Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit